Neovascular Age-Related Macular Degeneration
Physicians consider benefits, pitfalls of at-home monitoring for wet AMD
SEVILLE, Spain — Home monitoring of neovascular age-related macular degeneration, an interesting concept with many potential benefits, has entered the retina space in the U.S. with the Scanly Home OCT monitoring program from Notal Vision.
Community Case in nAMD
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Retinal Disease Digest on nAMD: Opportunities for Optometrists
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc., and Ocular Therapeutix, Inc.
Moderate to severe obstructive sleep apnea tied to higher odds for neovascular AMD
Moderate to severe obstructive sleep apnea was associated with significantly higher odds of having neovascular age-related macular degeneration, according to a study published in Clinical & Experimental Ophthalmology.
Dual inhibition with faricimab improves disease control in DME, neovascular AMD
Faricimab demonstrated noninferior vision gains and improved anatomical outcomes among patients with diabetic macular edema and neovascular age-related macular degeneration vs. aflibercept, according to study data.
Real-world data show visual acuity benefit of faricimab in neovascular AMD
KOLOA, Hawaii — Faricimab helped improve vision in previously untreated patients with neovascular age-related macular degeneration, according to a real-world study presented at Retina 2025.
Clinical Trial Updates in nAMD, DME, RVO, MacTel, and GA Management
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; Neurotech Pharmaceuticals, Inc.; Astellas; EyePoint Pharmaceuticals, Inc.; Opthea Ltd.; Topcon Healthcare, Inc.; Outlook Therapeutics; REGENXBIO Inc.; Ocuphire Pharma; and Carl Zeiss Meditec, Inc.
The Retina Radar With Dr. Arshad Khanani on Gene Therapy, TKIs, Emerging Treatments, and FDA Trial Guidance
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; AbbVie Inc.; Astellas; Apellis Pharmaceuticals, Inc.; Opthea; Alimera Sciences, Inc.; EyePoint Pharmaceuticals, Inc.; Neurotech Pharmaceuticals, Inc.; REGENXBIO Inc.; and Ocular Therapeutix, Inc.
Taming the Tide: Management of Persistent Retinal Fluid in nAMD and DME
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
In Case You Missed...Evolving Management Protocols for Retinal Diseases
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.